Welcome to our dedicated page for Cordyceps Sunshine Biotech Holdings Co SEC filings (Ticker: RAJAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RAJAF SEC filings page for Cordyceps Sunshine Biotech Holdings Co., Ltd. provides access to the company’s regulatory reports as a foreign private issuer under the Securities Exchange Act of 1934. The company identifies itself as a Form 20-F filer and also submits current reports on Form 6-K, which together outline its financial reporting practices, auditor relationships, and key corporate events.
Annual and periodic reports for Cordyceps Sunshine Biotech Holdings Co., Ltd. include consolidated balance sheets and consolidated statements of operations and comprehensive loss, changes in shareholders’ equity (deficit), and cash flows. These documents show how the company presents its group financial information and are central to understanding its historical performance and capital structure.
Current reports on Form 6-K highlight material developments, such as changes in the company’s independent registered public accounting firm. In one such filing, the company disclosed the termination of KCCW Accountancy Corp. and the appointment of YCM CPA INC. as its new auditor, along with statements about the absence of disagreements or reportable events and the nature of prior audit opinions.
On Stock Titan, users can review these RAJAF filings with AI-powered summaries that explain the key points of lengthy documents, such as auditor change disclosures and references to Regulation S-K requirements. Real-time updates from EDGAR help surface new Form 6-K and Form 20-F submissions, while insider transaction forms and other relevant filings, when available, can be examined alongside AI-generated insights to clarify complex accounting and reporting language.
Cordyceps Sunshine Biotech Holdings Co., Ltd. reported a change in its independent auditor. On November 15, 2025, the Board of Directors approved and ratified the appointment of YCM CPA INC. as the company’s new independent registered public accounting firm to audit its financial statements, effective the same day.
The report notes that during the two most recent fiscal years ended December 31, 2024 and 2023, and any subsequent interim periods before this engagement, neither the company nor anyone on its behalf consulted YCM CPA INC. on accounting matters. The filing also includes as an exhibit a letter from the previous auditor, KCCW Accountancy Corp., addressed to the U.S. Securities and Exchange Commission.
Cordyceps Sunshine Biotech Holdings Co., Ltd. amended its Form 20-F to provide updated annual disclosures about operations focused on Cordyceps and Antrodia products, manufacturing processes and cultivation techniques. The company reported training revenue of $154,107 for the period shown and a net income of $751,609 for the year ended December 31, 2023, reversing losses of $720,093 in 2022 and $491,006 in 2021. Management disclosed an accumulated deficit of $472,966 and negative working capital of $2,638,968 as of December 31, 2023, and stated substantial doubt about the company’s ability to continue as a going concern. The company recognized a $582,324 net gain from the reclassification and disposal of its Hong Kong subsidiary and recorded discontinued operations. Share ownership is highly concentrated with a controlling group holding approximately 59.3% of ordinary shares. Significant risks disclosed include customer and supplier concentration, regulatory and geopolitical risks related to PRC/Taiwan operations, and dependence on a limited product set.